Break it Down: Tryptamine Therapeutics reports positive results for Fibromyalgia patients

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Tryptamine Therapeutics’ (ASX:TYP) recent trial showing pain reduction in every patient.

The trial was undertaken with the University of Michigan and dosed the patients with Tryptamine’s oral psilocybin formulation.

Tune in to get the latest.

While Tryptamine Therapeutics is a Stockhead advertiser, it did not sponsor this content.